PeptideStack
5.2kquestions
20kanswers
220users

Why would VendorInvestigate report 96.8% where the supplier certificate says something higher?

Asked 19 May 2025Modified 11 months agoViewed 23k times
19

For reference: VendorInvestigate · 96.8%.

An unexpected observation, and I would like a differential rather than reassurance.

The conditions were within what I understood to be the acceptable range, which is why I am asking.

What would you check first, and what would you conclude from each outcome?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
shareeditfollowflag
ED
askede_dziedzic87k24819 May 2025

5 Answers

Accepted answer first, then by votes
53

Accepted answer

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

To be exact about it, retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
RS
answered · acceptedruaidhri_o_shea51k386 Aug 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
62

In practice, the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
TW
answeredtare_weight47k3828 Aug 2025
4Worth flagging that this changed in 2025, so older answers on the site are out of date. – ten_mg_vial 7 months ago
add a comment
42

Start from what the detector sees, because that tells you what the number means.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

To be exact about it, temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
TH
answeredtyndall_haze48k4817 Aug 2025
25

The part that matters: gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
KA
answeredkwn_analytical89k24826 Jul 2025
19

Mechanically, the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
EM
answeredeoin_mcgarry16k1814 Jun 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.